Overview

To Investigate Safety and Efficacy of NovoEight® (rFVIII) During Long-term Treatment of Haemophilia A in Japan

Status:
Completed
Trial end date:
2020-11-10
Target enrollment:
Participant gender:
Summary
This study is conducted in Asia. The aim of this study is to evaluate the safety and efficacy of NovoEight® (recombinant factor VIII) in patients with haemophilia A in Japan in the setting of routine clinical practice.
Details
Lead Sponsor:
Novo Nordisk A/S
Treatments:
Factor VIII